Upstream Bio (NASDAQ:UPB) Coverage Initiated at William Blair

William Blair initiated coverage on shares of Upstream Bio (NASDAQ:UPB) in a research report sent to investors on Tuesday morning, MarketBeat reports. The brokerage issued an outperform rating on the stock. William Blair also issued estimates for Upstream Bio’s Q4 2024 earnings at ($0.42) EPS, FY2025 earnings at ($2.36) EPS, FY2026 earnings at ($2.64) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($2.26) EPS.

Separately, TD Cowen started coverage on Upstream Bio in a research report on Tuesday. They set a “buy” rating on the stock.

Upstream Bio Stock Performance

Shares of NASDAQ:UPB opened at $26.18 on Tuesday. Upstream Bio has a 52-week low of $20.74 and a 52-week high of $29.46.

Insider Activity

In other Upstream Bio news, major shareholder Ai Upstream Llc acquired 1,175,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were bought at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the completion of the acquisition, the insider now directly owns 1,175,000 shares in the company, valued at $19,975,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Erez Chimovits purchased 825,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $14,025,000.00. Following the acquisition, the director now owns 4,554,873 shares of the company’s stock, valued at approximately $77,432,841. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ai Upstream Llc acquired 1,175,000 shares of Upstream Bio stock in a transaction that occurred on Tuesday, October 15th. The shares were purchased at an average price of $17.00 per share, with a total value of $19,975,000.00. Following the purchase, the insider now owns 1,175,000 shares in the company, valued at $19,975,000. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.